MA43801A - Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleur - Google Patents

Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleur

Info

Publication number
MA43801A
MA43801A MA043801A MA43801A MA43801A MA 43801 A MA43801 A MA 43801A MA 043801 A MA043801 A MA 043801A MA 43801 A MA43801 A MA 43801A MA 43801 A MA43801 A MA 43801A
Authority
MA
Morocco
Prior art keywords
arrestine
neurokinin
pain
beta
treatment
Prior art date
Application number
MA043801A
Other languages
English (en)
Inventor
Nigel Bunnett
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900635A external-priority patent/AU2016900635A0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA43801A publication Critical patent/MA43801A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043801A 2016-02-23 2017-02-23 Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleur MA43801A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2016900635A AU2016900635A0 (en) 2016-02-23 Inhibitors of beta-arrestin-Neurokinin 1 Receptor Interactions for the Treatment of Pain

Publications (1)

Publication Number Publication Date
MA43801A true MA43801A (fr) 2018-11-28

Family

ID=59684698

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043801A MA43801A (fr) 2016-02-23 2017-02-23 Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleur

Country Status (9)

Country Link
US (1) US20200206299A1 (fr)
EP (1) EP3419644A4 (fr)
JP (2) JP2019509277A (fr)
AU (1) AU2017223226A1 (fr)
CA (1) CA3015545A1 (fr)
EA (1) EA038338B1 (fr)
MA (1) MA43801A (fr)
MX (1) MX2018010174A (fr)
WO (1) WO2017143397A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220031849A1 (en) * 2018-10-22 2022-02-03 Takeda Pharmaceutical Company Limited Nanoparticle encapsulation to target g protein-coupled receptors in endosomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016547A1 (fr) * 1991-03-15 1992-10-01 The Children's Medical Center Corporation Controle des reponses a mediation par recepteurs nk-1 et diagnostiques associees
ES2239037T3 (es) * 1999-09-22 2005-09-16 Canbas Co., Ltd. Metodos y composiciones para inhibir la deteccion del ciclo celular en g2 y sensibilizar celulas a agentes dañinos del dna.
ES2552587B1 (es) * 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Also Published As

Publication number Publication date
EP3419644A1 (fr) 2019-01-02
US20200206299A1 (en) 2020-07-02
WO2017143397A1 (fr) 2017-08-31
JP2019509277A (ja) 2019-04-04
EA201891895A1 (ru) 2019-02-28
CA3015545A1 (fr) 2017-08-31
EA038338B1 (ru) 2021-08-11
AU2017223226A1 (en) 2018-08-30
JP2022064920A (ja) 2022-04-26
MX2018010174A (es) 2019-01-10
EP3419644A4 (fr) 2019-11-13

Similar Documents

Publication Publication Date Title
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA47719A (fr) Esketamine pour le traitement de la dépression
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA41449A (fr) Polythérapies pour le traitement de cancers
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA39753A (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
MA42999A (fr) Polythérapie pour le traitement de malignités
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA51738A (fr) Composés pour le traitement de la douleur
MA43800A (fr) Octréotide par voie orale pour le traitement de maladies
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee